---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-026931"
form_type: "8-K"
ticker: "DNTH"
cik: "0001690585"
company_name: "Dianthus Therapeutics, Inc. /DE/"
filed_at: "2023-02-07T23:59:59+00:00"
generated_at: "2026-06-19T23:00:12.682308+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Magenta Therapeutics to cut ~84% of workforce, CEO Gardner departs; CFO Mahoney becomes President

## Summary
- Board approved restructuring plan reducing workforce by up to 56 positions (~84%), substantially complete by Feb 17, 2023.
- Expected severance and related costs of approximately $5.4 million by end of February 2023.
- CEO Jason Gardner, CTO David Nichols, CCO Caren Deardorf, CPO Kristen Stants, and SVP Shawn Rose to leave the company.
- CFO/COO Stephen Mahoney named President; Gardner resigns from board effective Feb 7, 2023.
- Preliminary cash, cash equivalents, and marketable securities of ~$112M as of Dec 31, 2022 (unaudited).

## SEC filing metadata
- accession: 0001193125-23-026931
- form_type: 8-K
- ticker: DNTH
- cik: 0001690585
- company_name: Dianthus Therapeutics, Inc. /DE/
- filed_at: 2023-02-07T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 2.05, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1690585/000119312523026931/0001193125-23-026931-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1690585/000119312523026931/d434361d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-026931
- JSON: https://secwatch.observer/filing/0001193125-23-026931.json
- Plain text: https://secwatch.observer/filing/0001193125-23-026931.txt

## Key facts
- Restructurings & Charges
  Dianthus Therapeutics, Inc. /DE/ announced a restructuring with charges of $5.4 million (up to 56 positions, or approximately 84%).
  - Type: restructuring
  - Charge: $5.4 million
  - Headcount: up to 56 positions, or approximately 84%
  source text: or approximately 84%, to be substantially completed by February 17, 2023. As a result of the Plan, the Company expects to incur estimated severance and related costs of $5.4 million by the end of February 2023. Each departing employee of Magenta has played an integral role in the Company’s mission of improving stem cell transplant to enable access for more
  evidence_url: https://www.sec.gov/Archives/edgar/data/1690585/000119312523026931/0001193125-23-026931-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.